Table 1 Basic characteristics of the participants
Study | Duration | Inclusion criteria | Participants (T/C) | Age (years) | Male (%) | Outcome | ||
|---|---|---|---|---|---|---|---|---|
T | C | T | C | |||||
Jula 2015 | 12 weeks | Dyslipidemia patients | 120 (60/60) | 48.4 ± 6.2 | 48.0 ± 6.2 | 100 | 100 | Serum CoQ 10 concentrations |
Oranje 2001 | 3 months | Type 2 diabetes patients | 19 (9/10) | 64 ± 8 | 63 ± 8 | 100 | 70 | Plasma CoQ 10 concentrations |
Päivä 2005 | 8 weeks | Dyslipidemia patients | 48 (32/16) | 31–69 | 31–69 | N | N | Plasma CoQ 10 concentrations |
Strey 2005 | 6 weeks | Heart failure (NYHA II or III) with LVEF < 40% | 48 (24/24) | N | N | N | N | Plasma CoQ 10 concentrations |
Mortensen 1997 | 6Â weeks | Dyslipidemia patients | 45 (23/22) | 52.9 (32,69) | 54.8 (42,67) | 60.9 | 40.9 | Serum CoQ 10 concentrations |
Morrison 2017 | 24Â weeks | Patients with HIV | 147 (71/75) | 45 (41,51) | 47 (39,53) | 81 | 76 | Plasma CoQ 10 concentrations |
McMurray 2010 | 3 months | Heart failure (NYHA II or III) with LVEF < 40% | 1103 (551/552) | N | N | N | N | Serum CoQ 10 concentrations |
Ghirlanda 1993 | 3 months | Dyslipidemia patients | 30 (20/10) | 47 ± 8; 49 ± 10 | 47 ± 8 | 60; 50 | 70 | Plasma CoQ 10 concentrations |
Chitose 2014 | 6 months | STEMI patients | 75 (38/37) | 64.1 ± 11.8 | 65.8 ± 12.4 | 73.7 | 75.7 | Plasma CoQ 10 concentrations |
Berthold 2006 | 14 days | Healthy subjects | 48 (24/24) | 31.9 ± 8.8 | 28.6 ± 6.6 | N | N | Plasma CoQ 10 concentrations |
Barry 2001 | 4 weeks | Healthy subjects | 24 (12/12) | 26 ± 5 | 26 ± 5 | 41.7 | 41.7 | Plasma CoQ 10 concentrations |
Ashton et al. 2011 | 26 weeks | Heart failure (NYHA II or III) with LVEF < 40% | 69 (32/37) | N | N | N | N | Plasma CoQ 10 concentrations |